Skip to main content

Table 1 Main demographic, clinical and biochemical data of patients

From: Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study

 

With Fractures (n.18)

Without Fractures (n.82)

p

Age (years)

61 ± 13

61 ± 15

0.91

Male Sex (%)

61

63

0.86

Duration of RDT (months)

35 (14–75)

44 (18–101)

0.47

BMI (Kg/m2)

26.8 ± 4.8

25.1 ± 4.4

0.18

Height (cm)

159 ± 10

161 ± 10

0.48

Smokers (%)

50

48

0.85

Diabetics (%)

17

16

0.93

Treated with Beta blockers (%)

6

21

0.13

Treated with Calcitriol (%)

39

49

0.45

Treated with Ca-carbonate or Ca- acetate (%)

83

87

0.72

Treated with ESAs (%)

39

51

0.34

Hemodialysis/CAPD (n.)

15/3

51/31

0.09

History of previous fractures (%)

24

4

0.009

History of renal transplantation (%)

6

10

0.56

Haemoglobin (g/dL)

9.8 ± 2.6

10.5 ± 1.8

0.27

Serum Albumin (g/dl)

4.0 ± 0.7

3.8 ± 0.6

0.27

Serum Calcium (mmol/L)

4.5 ± 0.6

4.5 ± 0.6

0.73

Serum Phosphate (mg/dl)

6.0 ± 1.4

6.0 ± 1.6

0.92

Intact PTH (pg/mL)

319 (95–741)

135 (53–346)

0.04

intact PTH < 100 pg/ml (%)

28

46

0.15

intact PTH > 800 pg/ml (%)

22

6

0.03

Bone Alkaline phosphatase (μg/L)

15.0 (6.4-21.2)

12.7 (7.9-22.9)

0.89

Total Alkaline phospatase (UI/L)

67 (58–98)

69 (51–86)

0.88

IL-6 (pg/mL)

6.1 (3.2-8.0)

7.2 (3.3-11.0)

0.50

CRP (mg/L)

11.1 (3.5-28.2)

8.9 (3.4-19.1)

0.59

TNF-α (pg/mL)

12.0 (6.4-13.4)

7.8 (4.6-11.0)

0.02

  1. Data are expressed as mean ± SD, median and inter-quartile range or as percent frequency, as appropriate. Patients are divided into 2 groups on the basis incident fractures occurrence. P tests the differences among the groups. Significant differences between groups are indicated in bold. Intact PTH thresholds of < 100 and >800 pg/ml identify low and high bone turn-over, respectively [18]. ESAs = erythropoiesis-stimulating-agents.